据悉，MRG004A是针对差异化靶点、采用创新偶联技术的靶向组织因子(tissue factor，TF)的ADC药 物，通过Glyco Connect™定点偶联及Hydra Space™极性间隔技术连接TF靶向单抗与高效抗微管剂 MMAE，也是国内首款进入临床的TF ADC药物。 MRG004A已分别在中、美取得IND批准，并获FDA授予孤儿药资格认定和快速通道资格，用于治疗胰 腺癌。此前在美国及中国进行I期临床研究时已在胰腺癌、三阴乳腺癌及宫颈癌癌等适应症中观察到抗 肿瘤活性信号。 智通财经APP获悉，乐普生物-B(02157)涨超6%，截至发稿，涨5.81%，报9.66港元，成交额2.07亿港 元。 消息面上，8月11日，据国家药品监督管理局药品审评中心披露，乐普生物-B自主研发的TF ADC药物 MRG004A被纳入突破性治疗药物，这一重要进展标志着乐普生物在ADC药物研发领域取得又一重大突 破。 今年8月1日，乐普生物已启动MRG004A治疗胰腺癌的III期临床试验，期待MRG004A未来有望成为胰腺 癌患者的全新治疗选择。 ...

Core Viewpoint - Lepu Biopharma-B (02157) has seen a significant stock increase of over 6%, currently trading at 9.66 HKD with a transaction volume of 207 million HKD, following the announcement of its ADC drug MRG004A being included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Drug Development Progress - MRG004A is a targeted tissue factor (TF) ADC drug developed by Lepu Biopharma, utilizing innovative coupling technology and is the first TF ADC drug to enter clinical trials in China [1] - The drug has received IND approval in both China and the United States, along with orphan drug designation and fast track designation from the FDA for the treatment of pancreatic cancer [1] - Initial Phase I clinical studies in the US and China have shown anti-tumor activity signals in pancreatic cancer, triple-negative breast cancer, and cervical cancer [1] Group 2: Clinical Trials - On August 1, Lepu Biopharma initiated a Phase III clinical trial for MRG004A targeting pancreatic cancer, aiming to provide a new treatment option for patients [1]

Group 1 - The core viewpoint of the article highlights the recent stock performance of Lepu Biopharma-B, which saw a decline of 5.01% to 8.91 CNY per share, with a trading volume of 308 million CNY [1] - Lepu Biopharma focuses on biopharmaceutical research and development in the oncology treatment field, particularly in targeted therapy and immunotherapy, and has established a comprehensive end-to-end capability in drug discovery, clinical development, CMC, and GMP-compliant production [1] - The company has built a professional sales and marketing team aimed at meeting clinical needs and providing optimized and innovative drug solutions [1] Group 2 - As of the 2024 annual report, Lepu Biopharma reported total operating revenue of 368 million CNY and a net profit of -411 million CNY [2] - A forecast for the mid-2025 performance indicates an expected profit of approximately 24 million CNY, representing a year-on-year increase of 112.18% [3]

Core Viewpoint - The article discusses the significant market volatility following the mid-year earnings disclosures of Hong Kong-listed companies, highlighting the mixed performance and reactions of various firms in the market [1][13]. Group 1: Company Earnings Reports - On August 6, companies such as BeiGene, Cathay Pacific, and Uni-President China released their mid-year earnings, while others like Mifeng and Lepu Biopharma provided earnings forecasts [2]. - Cathay Pacific reported a revenue of HKD 54.309 billion for the first half of 2025, a year-on-year increase of 9.5%, and a net profit attributable to shareholders of HKD 3.651 billion, up 1.1% [4]. - BeiGene achieved total revenue of RMB 17.518 billion in the first half of 2025, marking a 46.0% year-on-year growth, and reported a net profit of RMB 450 million, indicating its first half-year profit [7]. Group 2: Market Reactions - Following the earnings announcements, Cathay Pacific's stock fell sharply, dropping 9.66% on August 6 and continuing to decline by 2.58% on August 7 [6]. - BeiGene's stock experienced a slight opening increase but fluctuated, with a drop exceeding 3% during the trading session [9]. - Lepu Biopharma's stock fell over 8% after announcing a projected net profit of at least RMB 24 million for the six months ending June 30, 2025, compared to a net loss of approximately RMB 197 million in the same period last year [9]. Group 3: Market Outlook - The article notes that the peak period for earnings disclosures in Hong Kong is approaching, with companies that report below expectations likely to face selling pressure [14]. - According to CITIC Securities, the overall revenue growth of the Hang Seng Index is expected to rise significantly year-on-year, although profit growth may moderate [14]. - China Galaxy Securities anticipates that the Hong Kong stock market may experience a volatile upward trend in the second half of 2025, supported by various policies and a relatively low valuation compared to global equity markets [15].

Market Overview - The A-share market showed strong performance with the Shanghai Composite Index steadily rising, while the Hong Kong stock market experienced a narrow fluctuation, closing up by 0.03% [1] - Concerns in the market are heightened due to the U.S. President Trump's shortened ultimatum for sanctions against Russia, now set at 10 days, with potential impacts on India and other countries [1] - The U.S. is also set to impose significant tariffs on semiconductor chips and pharmaceuticals, with drug tariffs reaching as high as 250% [1] Company Developments - Jingtai Technology announced a pipeline cooperation agreement with DoveTree worth approximately HKD 470 billion (USD 59.9 billion), leading to a stock surge of over 12% [2] - A-share company Weixin New Materials faced regulatory scrutiny after a stock price surge related to the "embodied intelligent robot" concept and control change expectations [2] - The Shanghai government released a plan for the development of the embodied intelligence industry, aiming for breakthroughs in core algorithms and technologies by 2027 [2] Industry Trends - The 2025 World Robot Conference is set to showcase over 100 new products, nearly double from last year, indicating a growing interest in robotics [3] - The U.S. student loan delinquency rate has reached 12.9%, the highest in 21 years, which may influence Federal Reserve decisions on interest rates [3] - The steel and paper industries are experiencing positive momentum, with companies like Maanshan Steel and Nine Dragons Paper seeing significant stock price increases [3] Defense Sector Insights - The military industry is gaining traction with significant contracts, such as the sale of the Hongqi-9 air defense system and the export of submarines to Pakistan [4] - China Shipbuilding Defense announced a profit increase of 213.25% to 267.73% for the first half of the year, leading to a stock rise of nearly 8% [4] Consumer Market Activity - The new consumption sector is becoming active, with companies like Pop Mart seeing increased attention at recent toy exhibitions [5] - The liquor industry is also responding to market trends, with new product launches and stock price increases [5] Aviation Sector Developments - Cathay Pacific announced an $8.1 billion order for 14 Boeing 777-9 aircraft, marking its first deal with Boeing in 12 years, despite concerns over the safety record of Boeing aircraft [7] - The long delivery timeline for the 777-9 model raises potential issues regarding aircraft aging and maintenance [7] Energy Sector Updates - The State Grid reported record electricity usage due to high temperatures, with peak load reaching 1.233 billion kilowatts, an increase of 53 million kilowatts from last year [8] - Coal prices have risen significantly, impacting the steel industry, which is maintaining high production levels [8] Automotive Sector Performance - XPeng Motors reported a record monthly delivery of 36,717 vehicles in July, a year-on-year increase of 229.4% [10] - The company is expanding its presence in Europe, with significant sales growth and new model launches [11][12]

Group 1 - The board meeting of Lepu Biopharma-B (02157.HK) is scheduled for August 20, 2025, to consider and approve the unaudited interim results for the six months ending June 30, 2025 [1] - The meeting will also discuss the proposal for an interim dividend distribution, if any, along with other matters [1]

公司于报告期转亏为盈主要得益于收入的大幅成长，其中主要包括与ArriVent BioPharma, Inc.就 MRG007开展的许可合作收入，以及普佑恒?(普特利单抗注射液)的销售收入增长。有关上述许可安排的 详情，请参阅本公司日期为2025年1月22日的公告。 格隆汇8月6日丨乐普生物-B(02157.HK)公布，截至2025年6月30日止六个月，预计公司将录得利润不少 于人民币2,400万元，而截至2024年6月30日止六个月的上年同期则亏损约人民币1.97亿元。这是公司首 次实现盈利。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU BIOPHARMA CO., LTD. 樂普生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2157） 董事會會議通告 樂普生物科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會 議將於2025年8月20日（星期三）舉行，藉以（其中包括）考慮及批准本公司及其附 屬公司截至2025年6月30日止六個月的未經審核中期業績及其發佈，以及考慮建 議派發中期股息（如有），以及處理其他事項。 承董事會命 樂普生物科技股份有限公司 董事長兼執行董事 蒲忠傑博士 中國，上海 2025年8月6日 於本公告日期，董事會包括執行董事蒲忠傑博士（董事長）及隋滋野博士（總經 理）；非執行董事蒲珏女士及秦怡然女士；以及獨立非執行董事周德敏先生、楊海 峰先生及華風茂先生。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 LEPU BIOPHARMA CO., LTD. 樂普生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2157） 正面盈利預告 本公告乃樂普生物科技股份有限公司（「本公司」，連同其附屬公司，「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）作 出。 本公司董事會（「董事會」）欣然告知本公司股東（「股東」）及潛在投資者，根據對 本公司截至2025年6月30日止六個月（「報告期」）的未經審核綜合管理賬目及董事 會現時所得資料的初步評估，預計本公司將錄得利潤不少於人民幣2,400萬元，而 截至2024年6月30日止六個月的上年同期則虧損約人民幣1.97億元。這是本公司 首次實現盈利。 本公司於報告期轉虧為盈主要得益於收入的大幅成長，其中主要包括與Arri ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02157 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,656,346,474 | RMB | | 1 RMB | | 1,656,346,474 | | 增加 / 減少 (-) | | | 148,093,364 | | | RMB | | 148,093,364 | | 本月底結存 | | | 1,804,439,838 | RMB | | 1 RMB | | ...